ANAB

$0.00

(

+0.00%

)
Quote details

stock

AnaptysBio Inc

NASDAQ | ANAB

23.58

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 26, 2025)

$659.60M

Market Cap

-

P/E Ratio

-4.39

EPS

$36.54

52 Week High

$12.21

52 Week Low

HEALTHCARE

Sector

ANAB Chart

Recent Chart
Price Action

ANAB Technicals

Tags:

ANAB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $91M
Total Revenue $91M
Cost Of Revenue $2.4M
Costof Goods And Services Sold $2.4M
Operating Income -$115M
Selling General And Administrative $42M
Research And Development $164M
Operating Expenses $206M
Investment Income Net -
Net Interest Income -$30M
Interest Income $20M
Interest Expense $50M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.4M
Income Before Tax -$145M
Income Tax Expense $3K
Interest And Debt Expense -
Net Income From Continuing Operations -$145M
Comprehensive Income Net Of Tax -
Ebit -$95M
Ebitda -$93M
Net Income -$145M

Revenue & Profitability

Earnings Performance

ANAB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $484M
Total Current Assets $432M
Cash And Cash Equivalents At Carrying Value $123M
Cash And Short Term Investments $123M
Inventory -
Current Net Receivables $41M
Total Non Current Assets $52M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $35M
Short Term Investments $262M
Other Current Assets $5.7M
Other Non Current Assets -
Total Liabilities $413M
Total Current Liabilities $45M
Current Accounts Payable $4M
Deferred Revenue -
Current Debt -
Short Term Debt $1.9M
Total Non Current Liabilities $368M
Capital Lease Obligations $16M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $16M
Other Current Liabilities $40M
Other Non Current Liabilities $353M
Total Shareholder Equity $71M
Treasury Stock -
Retained Earnings -$759M
Common Stock $30K
Common Stock Shares Outstanding $28M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$135M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.4M
Capital Expenditures $358K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $95M
Cashflow From Financing $127M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$456K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$145M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $91M
Total Revenue $91M
Cost Of Revenue $2.4M
Costof Goods And Services Sold $2.4M
Operating Income -$115M
Selling General And Administrative $42M
Research And Development $164M
Operating Expenses $206M
Investment Income Net -
Net Interest Income -$30M
Interest Income $20M
Interest Expense $50M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.4M
Income Before Tax -$145M
Income Tax Expense $3K
Interest And Debt Expense -
Net Income From Continuing Operations -$145M
Comprehensive Income Net Of Tax -
Ebit -$95M
Ebitda -$93M
Net Income -$145M

ANAB News

ANAB Profile

AnaptysBio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on advancing innovative therapeutic product candidates targeting inflammation and immuno-oncology. Leveraging its proprietary antibody development platforms, AnaptysBio aims to address significant unmet medical needs across various disease areas, with several candidates currently in clinical trials. The company's commitment to scientific excellence positions it strategically within the dynamic biopharmaceutical landscape, making it a compelling prospect for institutional investors interested in high-potential biotechnology opportunities.

DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
SNAP
-0.72%
$8.27
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
WOK
-5.22%
$0.08
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
SOFI
-0.49%
$27.98
ONDS
-1.16%
$7.66
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83
DVLT
+30.57%
$1.09
INTC
+4.44%
$35.50
GPUS
+19.56%
$0.45
CGBS
-39.47%
$0.03
DFLI
+38.45%
$0.52
YAAS
-31.07%
$0.06
SNAP
-0.72%
$8.27
NUAI
+33.33%
$1.84
NEHC
+33.33%
$1.84
CJET
+10.63%
$0.17
NVDA
+0.28%
$178.19
F
+3.35%
$12.01
PSTV
+9.60%
$0.61
DNN
-3.14%
$2.77
APLT
+121.34%
$1.24
TSLA
+4.01%
$440.40
RGTI
-2.86%
$31.18
BIAF
+55.13%
$5.29
PLUG
+0.42%
$2.37
CIFR
-1.62%
$11.47
NIO
-5.75%
$7.04
WOK
-5.22%
$0.08
ADAP
+15.74%
$0.14
AAL
-0.70%
$11.31
RIG
+0.94%
$3.19
IONZ
+5.83%
$4.34
TPIC
-45.91%
$0.12
AXDX
-61.36%
$0.03
MRM
+102.75%
$2.94
QBTS
+1.59%
$26.76
VALE
-1.74%
$10.70
IREN
-9.57%
$41.86
BTG
+1.44%
$4.92
BLMZ
+12.51%
$0.20
QUBT
-2.11%
$20.14
MARA
+0.37%
$16.13
KVUE
+1.54%
$16.42
RIOT
+5.67%
$17.69
KDLY
+7.69%
$1.26
ATCH
-4.25%
$0.79
AAPL
-0.54%
$255.46
PLTR
-0.86%
$177.57
SOUN
-2.50%
$15.94
BITF
-5.22%
$2.54
BBD
+0.91%
$3.30
TLRY
-3.36%
$1.14
WBD
-1.36%
$19.51
AMZN
+0.74%
$219.78
FCX
+1.16%
$35.75
BURU
-10.14%
$0.12
BMNR
+1.87%
$50.50
IXHL
-0.01%
$0.59
ETHD
-6.19%
$3.94
RMBL
+60.50%
$3.21
RXRX
+1.94%
$4.72
SHOT
+12.24%
$0.28
RR
+2.68%
$4.20
GRAB
-2.24%
$6.11
ADD
-25.47%
$0.05
RAYA
-3.15%
$0.04
RIVN
-0.95%
$15.59
SOFI
-0.49%
$27.98
ONDS
-1.16%
$7.66
BULL
+3.55%
$15.16
CVE
+0.39%
$17.77
CLSK
-5.26%
$12.96
SRM
+53.27%
$10.30
ACHR
-0.53%
$9.27
PFE
+0.67%
$23.76
IONQ
-3.09%
$67.28
BB
+6.66%
$4.96
JOBY
+1.57%
$16.11
NOK
-0.42%
$4.66
AMD
-1.12%
$159.46
CRWV
-4.98%
$120.34
CLF
+2.48%
$12.37
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BTE
+2.43%
$2.52
QS
+1.28%
$12.66
WLGS
-5.57%
$0.04
HIMS
+6.43%
$58.40
AQMS
+48.37%
$7.30
ABEV
0.00%
$2.29
MRVL
-0.76%
$83.17
ETWO
0.00%
$3.30
ORCL
-2.70%
$283.45
HBAN
+0.57%
$17.42
HOOD
-0.70%
$121.78
AG
+4.02%
$12.14
NWTN
-15.63%
$2.04
AIIO
-15.63%
$2.04
SDM
-86.40%
$1.85
T
+0.03%
$28.31
OKLO
-7.21%
$110.53
ITUB
+0.55%
$7.24
MU
+0.28%
$157.27
PCG
+3.67%
$14.97
AFMD
-34.94%
$0.18
WULF
-1.27%
$10.83

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.